UCB needs strong market strategy for its Rystiggo to fully compete in MG, says analyst
Gaining US Food and Drug Administration (FDA) approval for its news generalized myasthenia gravis (gMG) drug was positive news for Belgium’s largest drug maker UCB (Euronext: UCB), but the company will face challenges, according to sector analytics firm GlobalData.
The approval of Rystiggo (rozanolixizumab-noli), subcutaneouscomes, comes six months after the FDA accepted UCB’s priority review application. It is indicated for both anti-acetylcholine receptor (AChR) and anti-muscle-specific tyrosine kinase (MuSK) antibody positive patients diagnosed with generalized MG (gMG). Rystiggo will need an excellent marketing strategy in order to compete in the space, says GlobalData.
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in first-quarter 2024. Rystiggo is expected to become commercially available in the US during the third quarter this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze